Genpax Partners with IQVIA to Advance Genomics Solutions for AMR and Infectious Diseases
1st October 2024, London – Genax, a leader in pathogen genomics, is proud to announce a strategic partnership with IQVIA, a global provider of advanced health analytics, technology solutions, and clinical research services. Together, the two organizations aim to accelerate the fight against antimicrobial resistance (AMR) and other infectious diseases by leveraging cutting-edge genomics and data analytics solutions.
Through this collaboration, Genpax will provide cutting-edge genomics to enhance the surveillance and monitoring of AMR and infectious pathogens, enabling more precise identification, tracking, and response to emerging threats. By integrating Genpax's pathogen whole-genome sequencing (WGS) capabilities with IQVIA's expertise in healthcare data analytics and pharmaceutical insights, this partnership aims to deliver actionable insights that support public health authorities, healthcare providers, and pharmaceutical companies in addressing AMR and infectious diseases on a global scale.
IQVIA's Commitment to Public Health and Pharmaceutical Innovation
IQVIA has a long-standing commitment to improving public health outcomes through innovative pharmaceutical research and advanced data solutions. In the field of AMR, IQVIA has been at the forefront of initiatives that monitor antibiotic usage, promote responsible prescribing practices, and develop new treatments to combat resistant pathogens. Their work supports healthcare systems and pharmaceutical companies worldwide in tackling some of the most pressing healthcare challenges of our time.
"We are thrilled to partner with IQVIA, an organization that shares our vision for leveraging cutting-edge technology to improve global health outcomes," said Kieran Fontaine, Chief Strategy Officer of Genpax. "This partnership will enable us to combine our genomics expertise with IQVIA’s vast data and analytics capabilities, making a significant impact in the global fight against AMR and infectious diseases."
A Unified Approach to Combat AMR and Infectious Diseases
By providing actionable insights to healthcare systems, pharmaceutical partners, and public health organizations, Genax and IQVIA aim to develop solutions that will inform effective AMR prevention strategies, guide treatment protocols, and ultimately save lives.
For more information on the partnership and its initiatives, please visit genpax.co or contact kieran@genpax.co